H.C. Wainwright Reiterates Buy Rating on Generate Biomedicines (GENB) Oct 5, 2026 06:41AM
Roswell Park begins first human trial of AI-designed CAR T therapy Oct 1, 2026 07:03AM
H.C. Wainwright Reiterates Buy Rating on Generate Biomedicines (GENB) Sep 9, 2026 07:28AM
Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26' Sep 1, 2026 09:07AM
Generate Biomedicines (GENB) PT Raised to $30 at H.C. Wainwright Aug 28, 2026 07:05AM


Apr 13, 2026 06:13AM H.C. Wainwright Starts Generate Biomedicines (GENB) at Buy
Apr 2, 2026 08:02AM Generate Biomedicines (GENB) Reiterated at Overweight by Cantor Fitzgerald
Mar 24, 2026 06:07AM Cantor Fitzgerald Starts Generate Biomedicines (GENB) at Overweight
Mar 24, 2026 03:59AM Piper Sandler Starts Generate Biomedicines (GENB) at Overweight
Mar 24, 2026 03:35AM Morgan Stanley Starts Generate Biomedicines (GENB) at Overweight
Mar 24, 2026 02:31AM Goldman Sachs Starts Generate Biomedicines (GENB) at Buy
Mar 24, 2026 01:51AM Guggenheim Starts Generate Biomedicines (GENB) at Buy
Feb 23, 2026 06:45AM Generate Biomedicines plans up to $425 million U.S. IPO
Feb 23, 2026 06:42AM Generate Biomedicines (GENB) files for 25M share IPO at $15-$17/sh
Feb 4, 2026 05:07PM Generate Biomedicines (GENB) files for proposed IPO